Arcutis Biotherapeutics/$ARQT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Ticker

$ARQT
Primary listing

Industry

Biotechnology

Employees

342

ISIN

US03969K1088

ARQT Metrics

BasicAdvanced
$1.8B
-
-$1.04
1.78
-

What the Analysts think about ARQT

Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.

Bulls say / Bears say

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% received FDA approval for treating plaque psoriasis in adults and adolescents aged 12 and older, potentially expanding the company's market reach. (globenewswire.com)
The American Academy of Dermatology provided a strong recommendation for ZORYVE® (roflumilast) Cream 0.15% in updated guidelines for adult atopic dermatitis, enhancing its credibility among healthcare professionals. (globenewswire.com)
Arcutis reported a 413% increase in net product revenue for ZORYVE® in Q4 2024 compared to Q4 2023, indicating strong commercial performance. (globenewswire.com)
Arcutis announced a $100 million public equity offering at a discount to the market price, leading to an 18% drop in share value and potential dilution for existing shareholders. (proactiveinvestors.co.uk)
Insider selling activity, including significant share sales by company directors and insiders, may signal concerns about the company's future performance. (etfdailynews.com)
Despite positive revenue growth, Arcutis' stock has experienced significant volatility, with a reported 80% decline year-to-date as of October 2023, raising concerns about market confidence. (proactiveinvestors.co.uk)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

ARQT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ARQT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARQT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs